Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -51.03M | -57.21M | -62.01M | -75.48M | -85.82M |
| Total Depreciation and Amortization | 774.00K | 858.00K | 770.00K | 4.12M | 7.83M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.75M | 15.43M | 11.42M | 15.69M | 13.65M |
| Change in Net Operating Assets | -3.76M | -2.28M | -3.42M | 238.00K | -771.00K |
| Cash from Operations | -40.26M | -43.20M | -53.24M | -55.43M | -65.10M |
| Capital Expenditure | 23.00K | -462.00K | -486.00K | -628.00K | -1.42M |
| Sale of Property, Plant, and Equipment | 114.00K | 30.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 137.00K | -432.00K | -486.00K | -628.00K | -1.42M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00K | 2.00K | 33.00K | 33.00K | 125.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.00K | 2.00K | 33.00K | 33.00K | 125.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.12M | -43.63M | -53.69M | -56.02M | -66.40M |
